Multiple sclerosis patients who received oral doses of laquinimod, an immune-modulating drug, showed a 40% reduction in the cumulative number of active brain lesions seen on MRI scans over 36 weeks when compared with those who got a placebo, a multinational team of researchers reported. Two Mayo Clinic experts, however, underscored the need for more safety studies of the treatment.

Full Story:

Related Summaries